Company AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 11:41:24 2025-03-19 am EDT			5-day change	1st Jan Change
11,825.00 ^GBX	-0.18%		+1.44%	+12.90%

09:22am	Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns	RE
08:12am	Immunovant's muscle drug data underwhelms, shares gain on new drug promise	RE

Business description: AstraZeneca PLC

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (5.8%).

Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Number of employees: 94,300

Sales by Activity: AstraZeneca PLC

Fiscal Period: December	2020	2021	2022	2023	2024
Biopharmaceuticals	26.62B	37.42B	44.35B	45.81B	54.07B

See all business segments

Geographical breakdown of sales: AstraZeneca PLC

Fiscal Period: December	2020	2021	2022	2023	2024
United States	8.96B	12.05B	17.28B	18.12B	21.81B
China	5.34B	6B	5.74B	5.87B	6.42B
United Kingdom	1.74B	3.24B	3.12B	3.37B	4.74B
Other Rest of Europe	1.39B	1.95B	2.71B	3.11B	3.66B
Japan	2.57B	3.4B	3.99B	3.64B	3.45B
Germany	937M	1.49B	1.9B	2.1B	2.52B
Other Asia, Africa & Australasia	1.53B	2.38B	2.41B	2.04B	2.33B
Sweden	1.03B	2.32B	1.72B	1.7B	2.29B
Other Americas	761M	1.2B	1.18B	1.68B	2.25B
France	653M	915M	1.11B	1.15B	1.28B
Spain	398M	578M	738M	847M	994M
Italy	431M	577M	735M	813M	949M
Canada	596M	772M	1.17B	967M	937M
Australia	282M	547M	571M	390M	439M

See all geographic segments

Executive Committee: AstraZeneca PLC

Manager	Title	Age	Since
Pascal Soriot CEO	Chief Executive Officer	64	2012-09-30
Aradhana Sarin DFI	Director of Finance/CFO	51	2021-07-31
Regina Fritsche-Danielson CTO	Chief Tech/Sci/R&D Officer	61	-
Alberto Hegewisch CTO	Chief Tech/Sci/R&D Officer	-	2023-05-17
Sharon Barr CTO	Chief Tech/Sci/R&D Officer	-	2023-07-31

See ASTRAZENECA PLC governance

Composition of the Board of Directors: AstraZeneca PLC

Director	Title	Age	Since
Marcus Wallenberg BRD	Director/Board Member	69	1999-04-05
Pascal Soriot BRD	Director/Board Member	64	2012-09-30
Philip Broadley BRD	Director/Board Member	64	2017-04-26
Nazneen Rahman BRD	Director/Board Member	-	2017-05-31
Sherilyn McCoy BRD	Director/Board Member	67	2017-09-30
Deborah DiSanzo BRD	Director/Board Member	65	2017-11-30
Shu Kam Mok BRD	Director/Board Member	64	2018-12-31
Michel Demaré CHM	Chairman	68	2023-04-26
Euan Ashley BRD	Director/Board Member	-	2020-09-30
Diana Layfield BRD	Director/Board Member	-	2020-10-31

Composition of the Board of Directors

Shareholders: AstraZeneca PLC

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.2 %	65,120,892	4.2 %	9 813 M p
The Vanguard Group, Inc. 3.703 %	57,422,000	3.703 %	8 653 M p
Investor AB (Investment Company) 3.327 %	51,587,810	3.327 %	7 774 M p
BlackRock Investment Management (UK) Ltd. 3.176 %	49,240,173	3.176 %	7 420 M p
Norges Bank Investment Management 2.08 %	32,255,000	2.08 %	4 861 M p

Name	Equities	%	Valuation
T. Rowe Price International Ltd. 1.946 %	60,351,973	1.946 %	4 599 M p
PRIMECAP Management Co. 1.323 %	41,019,527	1.323 %	3 126 M p
Capital Research & Management Co. (International Investors) 1.209 %	37,507,159	1.209 %	2 858 M p
Wellington Trust Co., NA 1.194 %	37,038,885	1.194 %	2 823 M p
Merrill Lynch International 0.7748 %	24,026,966	0.7748 %	1 831 M p

Name	Equities	%	Valuation
Caixa DTVM SA 0.002778 %	258,533	0.002778 %	3 M p

List of ASTRAZENECA PLC shareholders

Holdings: AstraZeneca PLC

Name	Equities	%	Valuation
ASTRAZENECA PHARMA INDIA LIMITED 75%	18,750,000	75%	1,437,024,188 $
SWEDISH ORPHAN BIOVITRUM AB 9.84%	35,043,624	9.84%	1,030,243,647 $
NIOX GROUP PLC 16.61%	66,093,108	16.61%	52,263,125 $
CELLECTIS S.A. 15.98%	16,000,000	15.98%	21,798,400 $
INNATE PHARMA 8.93%	7,485,500	8.93%	16,542,955 $
MONOPAR THERAPEUTICS INC. 6.35%	387,329	6.35%	13,599,121 $
CONDUIT PHARMACEUTICALS INC. 2.02%	95,045	2.02%	114,054 $

Company details: AstraZeneca PLC

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk

Group companies: AstraZeneca PLC

Name	Category and Sector
Astrazeneca Treasury BV
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Miscellaneous Commercial Services
AstraZeneca Employee Share Trust Ltd. AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The company is located in the UK.	Miscellaneous Commercial Services
AstraZeneca UK Ltd. AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.	Miscellaneous Commercial Services
Alexion Pharmaceuticals, Inc. /New/

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ASTRAZENECA PLC	-0.18%	+1.44%	+15.55%	+22.73%	239B
ELI LILLY AND COMPANY	+1.44%	+1.49%	+7.93%	+187.97%	739B
JOHNSON & JOHNSON	-0.80%	-0.05%	+4.20%	-7.43%	396B
ABBVIE INC.	-1.08%	-0.14%	+17.87%	+32.31%	378B
NOVO NORDISK A/S	-0.25%	+7.66%	-39.09%	+46.51%	358B
ROCHE HOLDING AG	-1.05%	-0.29%	+33.77%	-16.55%	282B
MERCK & CO., INC.	-0.05%	+1.40%	-22.54%	+19.73%	239B
NOVARTIS AG	+0.16%	+2.27%	+15.18%	+22.21%	222B
AMGEN INC.	-1.19%	+0.65%	+15.75%	+33.09%	171B
PFIZER, INC.	+0.13%	+2.49%	-4.63%	-51.37%	149B
Average	-0.29%	+1.40%	+4.40%	+28.92%	317.21B
Weighted average by Cap.	-0.08%	+1.13%	+4.26%	+54.59%